PRKAA2 and metabolic dysfunction-associated steatotic liver disease: In conclusion, this study revealed that hepatic KISS1R signaling system inhibits NAFLD via AMPK, uncovering KISS1R as a promising therapeutic target for the treatment of NAFLD.